It's interesting that anyone other than the R&D arm of the pharma industry even cares how it works.
From the medical side what's important is what risk/benefit which is independent.
Antidepressant as a term is really only for convenience which the medications themselves being quite broad in action.
Antipsychotics too are having a bit of a revolution, the first generation seemed to all be about D2 blockade, the second generation acting on 5HT-2a much more than D2. Finally, pimavaserin acting only on seratonin (5HT-2a) and not on dopamine at all [0] now there's SEP-363856 [1] which has action not at D2 or 5HT-2A but TAAR1 and 5HT-1A.
The point is that psychiatrists are not particularly married to any mode of action or mechanism. Only the results.
From the medical side what's important is what risk/benefit which is independent.
Antidepressant as a term is really only for convenience which the medications themselves being quite broad in action.
Antipsychotics too are having a bit of a revolution, the first generation seemed to all be about D2 blockade, the second generation acting on 5HT-2a much more than D2. Finally, pimavaserin acting only on seratonin (5HT-2a) and not on dopamine at all [0] now there's SEP-363856 [1] which has action not at D2 or 5HT-2A but TAAR1 and 5HT-1A.
The point is that psychiatrists are not particularly married to any mode of action or mechanism. Only the results.
[0] https://nbn2r.com/search#drug/90
[1] https://en.wikipedia.org/wiki/Ulotaront